The FDA approved the use of adjuvant atezolizumab in stage II to IIIA NSCLC with PD-L1 expression ≥ 1% on tumor cells, whereas NCCN guidelines support the use of adjuvant atezolizumab in stage IIB–IIIA, stage IIIB (T3, N2), or high-risk stage IIA NSCLC with PD-L1 ≥ 1% [6]. The gene discussed is CD274; the disease is neoplasm.